GW26-e0100 Comparison of Iodixanol and Iopromide in Patients with Renal Insufficiency and Congestive Heart Failure undergoing Coronary Angiography by Minimally-invasive Hemodynamic Monitor  by Qian, Geng & Chen, Yundai
C164 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 6 , S U P P L S , 2 0 1 5RESULTS The number of vessels diseased and per capita implant
frame in the PCI group with elevated hs-cTnT is higher than the PCI
group with normal hs-cTnT (P<0.05). The incidence rate of cardio-
vascular events in the PCI group with elevated hs-cTnT is higher than
the PCI group with normal hs-cTnT and the control group (P<0.05);
However, there is no signiﬁcant difference between the PCI group
with normal hs-cTnT and the control group.
CONCLUSIONS Hs-cTnT combined with FFR can guide the coronary
artery interventional therapy in treating critical lesion, and predict
the rate of major adverse cardiac events after interventional therapy.
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Patients with residual ischemia on intracoronary electrocardiogram after
stenting coronary bifurcation lesions have more angina at 12 month follow-
up – insights form intracoronary electrocardiography based strategy for
treatment of coronary bifurcation lesions
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OBJECTIVES Toevaluate inﬂuence of icECG-guided strategy for treatment
of side branch after stentingmain vessel (in provisional T-stenting strategy)
on one year angina or new-onset heart failure symptoms recurrence
METHODS 132 patients with stable or unstable angina followed at
least 12 months. Inclusion criteria – coronary bifurcation lesions,
RVD  2.5 – 4.5 mm; SB RVD  2.0 mm. Exclusion criteria: STEMI; LM
stenosis; CTOs; lesion of interest located at infarct-related artery;
LVEF < 30%; moderate/severe degree valvular disease; primary car-
diomyopathy; L/RBBB, atrial ﬁbrillation/ﬂutter with no identiﬁable
isoelectric line. Intracoronary ECG-guided strategy was followed: after
stenting main vessel, icECG from SB was recorded; if ST-segment
elevation was recorded then balloon dilatation þ/- kissing balloon
inﬂation was performed. Depending on results from icECG (occur-
rence of ST-segment elevation, STE) 6 groups were formed: Group 1 -
SB%DS>50% after stenting, with icECG STE in side branch region, no
further intervention on SB. Group 2 - SB%DS>50% after stenting, no
icECG STE; no additional treatment of side branch. Group 3 - SB%
DS>50% after stenting, icECG STE in side branch region, balloon
dilatation of side branch ostium and icECG STE was eliminated af-
terwards. Group 4 - SB%DS>50% after stenting, icECG STE in side
branch, ballooning of SB ostium, but sustained icECG STE on ﬁnal
record from side branch. Group 5 - icECG STE in side branch region
after stenting, but ostial stenosis was less than 50% and no treatment
performed. Group 0 – SB%DS <50% after stenting and no icECG STE.
RESULTS The rates of angina recurrence or new-onset heart failure at 12
months are presented in the table. On multivariate analysis, the residual
ischemia on icECG was independently associated with recurrent angina or
new-onset heart failure (HR ¼ 3.731, CI ¼ 1.085 – 27.027, p¼.037).Angina or NO CHF (-) Angina or NO CHF (D) pGroup 0 21 (100%) 0 (0%) p ¼ 0.003
Group 1 8 (67%) 4 (33%)Group 2 28 (85%) 5 (15%)Group 3 29 (83%) 6 (17%)Group 4 12 (57%) 9 (43%)Group 5 5 (50%) 5 (50%)CONCLUSIONS At 12 months patients with residual ischemia on
icECG had more recurrent angina or new-onset heart failure symp-
toms. That was independent from chosen treatment strategy for side
branch stenosis.
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Impact of Tongguan Capsule on periprocedural myocardial injury
undergoing percutaneous coronary intervention in coronary heart disease
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OBJECTIVES Percutaneous coronary intervention (PCI) has become a
frequently procedure for coronary revascularization in patients withCoronary heart disease (CHD). Although technical advances in PCI are
becoming better and more effective medical therapy can be used, the
incidence of periprocedural myocardial injury (PMI) is still high,
which is associated with increased subsequent mortality. Here we
aimed to analyze the effects of Chinese herbal compound Tongguan
Capsule (TGC) on PMI underwent elective PCI in CHD.
METHODS We retrospectively enrolled 288 consecutive patients with
normal preprocedural cTnI underwent elective PCI. Patients were
divided into the two groups according to whether or not took TGC at
least one day before PCI: TGC group (n¼104) and non-TGC group
(n¼186). PMI was evaluated by cTnI analysis within 24 hours. The
relationship of TGC with peak cTnI values after PCI was examined.
RESULTS Peak postprocedural cTnI >1upper limit of normal (ULN),
>3ULN, and >5ULN were detected in 159(55.2%), 120(41.7%) and
103(35.8%), respectively. The baseline clinical and procedural char-
acteristics between the two groups were not statistically signiﬁcant
(P > 0.05). CTnI values of the two group were not statistically sig-
niﬁcant (P ¼0.828) before PCI, but non-TGC group was signiﬁcant
higher than TGC group (P ¼0.018) after PCI. Then, TGC group post-
operative cTnI elevation 1xULN was 47 patients (45.2%), and non-TGC
group was 112 patients (60.9%), the difference between the two
groups were statistically signiﬁcant (P ¼0.010). Furthermore, TGC
group postprocedural cTnI elevation 3xULN and 5xULN were 34
patients (32.7%) and 29 patients (27.9%), respectively. Non-TGC group
postprocedural cTnI elevation 3xULN and 5xULN were 86 patients
(46.7%) and 74 (40.2%), respectively, the difference incidence of PMI
between the two groups were statistically signiﬁcant (P <0.05). In the
multivariable model, TGC group was associated with lower risk of
postprocedural cTnI elevation above 1ULN (OR, 0.51; 95% CI, 0.29–
0.89; P¼0.019), 3ULN (OR, 0.51; 95% CI, 0.28–0.92; P¼0.025), 5ULN
(OR, 0.52; 95% CI, 0.28-0.98; P¼0.045), respectively.
CONCLUSIONS Patients with CHD took TGC before PCI might effec-
tively reduce the degree of postprocedural cTnI elevation and
decrease the incidence of PMI, suggesting the Chinese herbal com-
pound TGC might play an important role in myocardial protection.
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OBJECTIVES Preoperative low albumin level is considered to be a risk
factor for acute kidney injury in surgical patients. However, the
impact of hypoalbuminemia on contrast-induced nephropathy (CIN)
in patients undergoing percutaneous coronary intervention (PCI) is
unknown.
METHODS A total of 674 consecutive patients who underwent selec-
tive PCI were included, in which 294 patients had a preoperative al-
bumin level <3.5g/dL (hypoalbuminemia), and 380 patients had a
preoperative albumin level 3.5g/dL. CIN was deﬁned as an elevation
of serum creatinine by 25% or 0.5mg/dl from baseline within 48h
after PCI. Multivariate logistic regression and propensity analyses
were performed to evaluate the association between hypo-
albuminemia and CIN.
RESULTS At last, 36 (12.24%) patients with hypoalbuminemia devel-
oped CIN, comparing to that 28 (7.37%) patients without hypo-
albuminemia developed CIN (p¼0.032). After adjustment for the other
risk factors (old age, anemia, eGFR<60ml/min$1.73m2, and diabetes
mellitus), hypoalbuminemia was independently associated with CIN
[multivariable logistic analysis: OR 1.452(1.106,2.224), p¼0.008; pro-
pensity analysis: OR 1.362(1.112-2.235), p¼ 0.012].
CONCLUSIONS Hypoalbuminemia might serve as a independent
predictor in patients undergoing CIN.
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Comparison of Iodixanol and Iopromide in Patients with Renal Insufﬁciency
and Congestive Heart Failure undergoing Coronary Angiography by
Minimally-invasive Hemodynamic Monitor
Geng Qian, Yundai Chen
Department of Cardiology, Chinese People’s Liberation Army General
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OBJECTIVES Intra-arterial iodinated contrast media (CM) may in-
crease the cardiac preload in the process of percutaneous coronary
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(CKD) and congestive heart failure (CHF). The objective of this study
was to investigate the impact of CM with different osmolality on
cardiac preload in patients with CKD and CHF.
METHODS 90 non-ST elevation acute coronary syndromes (NSTE-
ACS) patients with renal insufﬁciency (estimated glomerular ﬁltration
rate60 ml/min) and CHF were equally randomized to receive either
iodixanol 320 (Visipaque) or iopromide 370 (Ultravist) in PCI pro-
cesses. We applied pulse indicator continuous cardiac output (PICCO)
technology to observe the change of hemodynamic indexes in the
perioperative period. Contrast induced nephropathy (CIN) was
deﬁned as increase in serum creatinine 0.5 mg/dl or >25% from
baseline.
RESULTS Baseline characteristics were well-matched between the 2
groups. CIN developed in 21 patients (23.3%), and there was no sig-
niﬁcant difference between the iodixanol and iopromide groups (17.8%
vs. 28.9%, P¼0.213). Extravascular lung water index (EVLWI), global
end-diastolic index (GEDI) and central venous pressure (CVP) were
all signiﬁcantly increased after application of CM in the iopromide
group (13.13.8 ml/kg vs. 8.43.2 ml/kg in EVLWI; 1381472 ml/m2
vs. 962362 ml/m2 in GEDI; 145 mmHg vs. 115 mmHg in CVP; all
P<0.001), and the changes of these preload indexes in the iopromide
group were all signiﬁcantly greater than in the iodixanol group (all
P<0.05). The incidence of adverse events in terms of death, myocardial
infarction, repeat revascularization did not differ between the two
groups, but the incidence of acute heart failure in the iopromide group
was signiﬁcantly higher than the iodixanol group (P¼0.048).
CONCLUSIONS Iopromide could signiﬁcantly increase cardiac pre-
load in patients with CKD and CHF as compared to iso-osmolar CM
iodixanol, and this is associated with a higher occurrence of acute
heart failure event during the perioperative stage.
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Central Venous Pressure Guided Hydration Reduces Contrast Induced
Nephropathy in Patients Undergoing Coronary Procedures with Chronic
Kidney Disease and Congestive Heart Failure
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OBJECTIVES Patients at moderate or high risk for contrast induced
nephropathy (CIN) should receive sufﬁcient hydration before contrast
application to prevent CIN. The guidelines recommend controlling
rate of ﬂuid administration in patients with heart failure, but inade-
quate hydration markedly increases the incidence of CIN. We expect
to explore an individual hydration method for patients with conges-
tive heart failure (CHF) and chronic kidney disease (CKD) to reduce
the incidence of CIN and at the same time to avoid the acute heart
failure for these patients.
METHODS This prospective, randomized, double-blind, comparative
clinical trial enrolled 264 consecutive patients with CHF and CKD
undergoing coronary procedures. These patients randomly received
either central venous pressure (CVP) guided hydration (n¼132) or
standard intravenous isotonic saline hydration (control group; n¼132).
In the CVP guided group, hydration infusion rate was automatically
adjusted according to CVP level every hour, and both study groups
received intravenous ﬂuids for the same duration but at different
rates. CIN was deﬁned as an absolute increase in serum creatinine
(SCr) > 0.5 mg/dL (44.2 mmol/L) or a relative increase >25% compared
to baseline SCr. Adverse events were assessed by 3 months follow-up
and all such events were classiﬁed by staff who were masked to
treatment assignment. This trial is registered with ClinicalTrials.gov,
number NCT02405377.
RESULTS Baseline characteristics were well-matched between the
two groups. Mean baseline SCr and the predictive CIN risk score were
comparable in the two groups. The total mean volume of isotonic
saline administered in the CVP guided hydration group is signiﬁcantly
higher than the control group (1827497 vs. 1202247; p<0.001). CIN
occurred less frequently in CVP guided hydration group than in the
control group (15.9% vs. 29.5%; p¼0.006). The incidences of acute
heart failure (acute pulmonary edema) during the perioperative
period did not differ between the two groups (6.8% vs. 7.6%;
p¼0.500). A lower incidence of cumulative 90-day adverse events
(renal replacement therapy, acute myocardial infarction, acute heart
failure and death) was also observed in CVP guided hydration patients
than in controls (8.3% vs. 20.5%; p¼0.004).
CONCLUSIONS CVP guided ﬂuid administration can safely and
effectively reduce the risk of CIN for patients with CKD and CHF.GW26-e0451
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OBJECTIVES To investigate the long noncoding RNA (lncRNA)
NONHSAT112178 as a biomarker for coronary artery disease (CAD) in
peripheral blood monocyte cells (PBMC).
METHODS RT-qPCR was performed to validate the microarray results,
ROC curve was applied to study the potential of NONHSAT112178 as a
biomarker. Diagnostic models from NONHSAT112178 alone or combi-
nation of risk factors were constructed by Fisher criteria. The function
of NONHSAT112178 was conﬁrmed in THP-1 cell line by siRNA.
RESULTS The result indicated the expression of NONHSAT112178 in
PBMCs from CAD patients increased more than twice times by
microarray analysis and RT-qPCR compared with the control group,
P<0.05. Further validated independently in a population (2020),
NONHSAT112178 expression (about 2.2-fold in CAD patients), was
consistent with the result from lncRNA microarray. The predictive
value of NONHSAT112178 was assessed in a larger population of 211
CAD patients and 171 controls. Using a diagnostic model by Fisher
criteria, considered the risk factors, the corresponding optimal
sensitivity was increased from 70.00% to 82.00%, the speciﬁcity was
slightly decreased from 94.00% to 78.00%, respectively. AUC was
increased from 0.727 to 0.785 (P¼0.001), from 0.712 to 0.768
(P¼0.010), and from 0.769 to 0.835 (P¼0.069), in original, training and
test set, respectively. Moreover, in a prospective study, we found the
sensitivity of NONHSAT112178 was increased from 68.00% to 76.00%
and speciﬁcity was decreased from 90.00% to 82.50%, respectively.
NONHSAT112178 was also found to be speciﬁc in CAD compared with
other cardiovascular diseases. Finally, we found neighboring protein-
coding gene peroxisome proliferator-activated receptor delta
(PPARD), and its target genes adipose differentiation-related protein
(ADRP) and angiopoietin-like 4 (ANGPTL4) are all transrepressed by
NONHSAT112178.
CONCLUSIONS Our present study indicated that NONHSAT112178
with function, neighboring protein-coding gene PPARD, combination
of risk factors can be used as a biomarker for CAD.
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Guided Low-Dose Furosemide for Preventing Contrast-induced
Nephropathy in the Percutaneous Coronary Intervention
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OBJECTIVES This study was to evaluate on the prophylactic effect of
low-dose furosemide guided by left ventricular end-diastolic pressure
and brain natriuretic peptide on contrast-induced nephropathy of
patients with percutaneous coronary intervention on basis of
adequate hydration.
METHODS The patients of PCI(Percutaneous Coronary Intervention)
were recruited. The inclusion criteria: 1.male or female, 18-75 years
old; 2.sign the informed consent. Exclusion criteria: 1.inability to
obtain consent from participants; 2.primary percutaneous coronary
intervention for ST-segment elevation myocardial infarction; 3.renal
replacement therapy; 4.exposure to radiographic contrast media
within the previous 2 days; 5.allergy to radiographic contrast media;
6.acute decompensated heart failure; 7.severe valvular heart disease;
8.mechanical aortic prosthesis; 9.left ventricular thrombus; 10.history
of kidney or heart transplantation. The patients were divided into two
groups: the control group and experimental group, the basic charac-
teristics and routine examinations were recorded. All patients were
given standard hydration process according to the guideline, the
control group was administered 20 mg furosemide right after the
procedure, but the experimental group was treated individually, ac-
cording to the result of BNP(Brain Natriuretic Peptide) and LVEDP
(Left Ventricular End-Diastolic Pressure). Only the patients of
LVEDP15mmHg or BNP100pg/ml or BNP more than 50% of preop-
erative values were given 20 mg furosemide and the rest had no
special treatment. The creatinine was obtained before and 48h after
the PCI procedures, so the creatinine clearance rate and glomerular
ﬁltration rate could be calculated, also the all-cause mortality,
